Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTX NASDAQ:FATE NASDAQ:KPTI NASDAQ:TIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$2.43+1.5%$2.62$0.49▼$3.62$224.19M1.571.35 million shs79,112 shsFATEFate Therapeutics$2.12-3.0%$1.37$0.91▼$2.46$245.93M2.131.87 million shs913,140 shsKPTIKaryopharm Therapeutics$8.82+0.1%$7.94$3.65▼$10.99$198.89M0.8813,075 shs66,674 shsTILInstil Bio$8.12-0.1%$8.38$5.67▼$42.79$55.05M1.9488,492 shs5,969 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics+0.42%+5.29%-4.02%+1.27%+213.85%FATEFate Therapeutics-8.79%+42.48%+75.81%+100.00%+109.62%KPTIKaryopharm Therapeutics+1.97%+0.46%+10.13%+33.89%+46.59%TILInstil Bio-0.37%+2.91%+0.25%+5.72%-38.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$2.43+1.5%$2.62$0.49▼$3.62$224.19M1.571.35 million shs79,112 shsFATEFate Therapeutics$2.12-3.0%$1.37$0.91▼$2.46$245.93M2.131.87 million shs913,140 shsKPTIKaryopharm Therapeutics$8.82+0.1%$7.94$3.65▼$10.99$198.89M0.8813,075 shs66,674 shsTILInstil Bio$8.12-0.1%$8.38$5.67▼$42.79$55.05M1.9488,492 shs5,969 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics+0.42%+5.29%-4.02%+1.27%+213.85%FATEFate Therapeutics-8.79%+42.48%+75.81%+100.00%+109.62%KPTIKaryopharm Therapeutics+1.97%+0.46%+10.13%+33.89%+46.59%TILInstil Bio-0.37%+2.91%+0.25%+5.72%-38.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTXContext Therapeutics 2.88Moderate Buy$6.60172.16% UpsideFATEFate Therapeutics 2.25Hold$4.50112.77% UpsideKPTIKaryopharm Therapeutics 2.88Moderate Buy$16.1483.03% UpsideTILInstil Bio 1.75Reduce$66.00712.81% UpsideCurrent Analyst Ratings BreakdownLatest TIL, CNTX, KPTI, and FATE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026KPTIKaryopharm Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $13.005/4/2026FATEFate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $7.004/29/2026FATEFate Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026KPTIKaryopharm Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$8.00 ➝ $16.004/20/2026CNTXContext Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/30/2026KPTIKaryopharm Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$12.00 ➝ $8.003/27/2026TILInstil Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/25/2026KPTIKaryopharm Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$21.00 ➝ $15.003/25/2026KPTIKaryopharm Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $8.003/24/2026CNTXContext Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.003/24/2026CNTXContext Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTXContext TherapeuticsN/AN/AN/AN/A$0.66 per shareN/AFATEFate Therapeutics$6.65M36.98N/AN/A$1.80 per share1.18KPTIKaryopharm Therapeutics$146.07M1.36N/AN/A($16.00) per share-0.55TILInstil BioN/AN/AN/AN/A$16.79 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%N/AFATEFate Therapeutics-$136.32M-$1.15N/AN/AN/A-2,051.08%-55.02%-38.05%5/12/2026 (Estimated)KPTIKaryopharm Therapeutics-$196.04M-$16.62N/AN/AN/A-134.21%N/A-122.29%5/14/2026 (Estimated)TILInstil Bio-$71.37M-$10.78N/AN/AN/AN/A-55.88%-32.31%5/12/2026 (Estimated)Latest TIL, CNTX, KPTI, and FATE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026KPTIKaryopharm Therapeutics-$1.45N/AN/AN/A$31.40 millionN/A5/12/2026Q1 2026FATEFate Therapeutics-$0.29N/AN/AN/A$1.49 millionN/A5/12/2026N/ATILInstil Bio-$0.62N/AN/AN/AN/AN/A5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A3/27/2026Q4 2025TILInstil Bio-$2.31-$1.21+$1.10-$1.21$1.90 millionN/A3/23/2026Q4 2025CNTXContext Therapeutics-$0.11-$0.14-$0.03-$0.14N/AN/A2/26/2026Q4 2025FATEFate Therapeutics-$0.27-$0.27N/A-$0.27$1.20 million$1.37 million2/13/2026Q4 2025KPTIKaryopharm Therapeutics-$2.26-$2.23+$0.03-$5.71$33.16 million$34.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTXContext TherapeuticsN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTXContext TherapeuticsN/A8.968.96FATEFate TherapeuticsN/A5.795.79KPTIKaryopharm TherapeuticsN/A1.121.08TILInstil Bio0.7439.5339.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTXContext Therapeutics14.03%FATEFate Therapeutics97.54%KPTIKaryopharm Therapeutics66.44%TILInstil Bio60.56%Insider OwnershipCompanyInsider OwnershipCNTXContext Therapeutics4.80%FATEFate Therapeutics4.74%KPTIKaryopharm Therapeutics1.68%TILInstil Bio47.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTXContext Therapeutics791.88 million87.47 millionNot OptionableFATEFate Therapeutics550116.28 million110.77 millionOptionableKPTIKaryopharm Therapeutics38022.55 million22.17 millionOptionableTILInstil Bio4106.78 million3.59 millionNo DataTIL, CNTX, KPTI, and FATE HeadlinesRecent News About These CompaniesInstil Bio (TIL) Price Target Increased by 24.53% to 67.32April 9, 2026 | msn.comInstil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 27, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILFebruary 12, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILFebruary 3, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 29, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio,January 27, 2026 | bakersfield.comBINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 27, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 22, 2026 | prnewswire.comTIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & KorsinskyJanuary 20, 2026 | newsfilecorp.comNINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 20, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 15, 2026 | prnewswire.comInstil Bio (TIL) Price Target Decreased by 45.17% to 53.55January 14, 2026 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 13, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 8, 2026 | prnewswire.comHC Wainwright & Co. downgrades Instil Bio (TIL)January 8, 2026 | msn.comArrowhead showcases early obesity data; Instil bails on PD-1/VEGF drugJanuary 7, 2026 | biopharmadive.comBInstil Bio shares slide on discontinuation of lead clinical programsJanuary 6, 2026 | proactiveinvestors.comInstil Bio Pulls Plug On Lead Drug DevelopmentJanuary 6, 2026 | benzinga.comInstil Bio stock falls after subsidiary discontinues AXN-2510 developmentJanuary 6, 2026 | in.investing.comInstil Bio Discontinues Clinical Development of AXN-2510, Ends Agreement with ImmuneOncoJanuary 6, 2026 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThese 3 Defense Giants Beat Q1 Estimates—So Why Did Their Stocks Still Fall?By Jessica Mitacek | April 22, 2026ASML Falls Post-Earnings, Chip-Making Expansion Anchors OutlookBy Leo Miller | April 16, 2026Pipelines and Automation: 2 Energy Plays Built for Any Oil PriceBy Chris Markoch | April 26, 2026Amazon Stock Up 30%: Is AMZN Still a Buy Before Earnings?By Sam Quirke | April 22, 20263 Low-Volatility ETFs for Peace of Mind in Turbulent TimesBy Nathan Reiff | April 13, 2026TIL, CNTX, KPTI, and FATE Company DescriptionsContext Therapeutics NASDAQ:CNTX$2.42 +0.04 (+1.46%) As of 11:52 AM Eastern This is a fair market value price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Fate Therapeutics NASDAQ:FATE$2.12 -0.07 (-2.98%) As of 11:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Karyopharm Therapeutics NASDAQ:KPTI$8.82 +0.01 (+0.11%) As of 11:53 AM Eastern This is a fair market value price provided by Massive. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Instil Bio NASDAQ:TIL$8.12 -0.01 (-0.12%) As of 11:53 AM Eastern This is a fair market value price provided by Massive. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
